These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 29125233

  • 21. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D, Yang D, Pastorino F, Emionite L, Cilli M, Daga A, Destafanis E, Di Fiore A, Piaggio F, Brignole C, Xu X, Liang C, Gibbons J, Ponzoni M, Perri P.
    Oncotarget; 2015 Oct 06; 6(30):28774-89. PubMed ID: 26299615
    [Abstract] [Full Text] [Related]

  • 22. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer.
    Nanjo S, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, Katakami N, Okada Y, Yano S.
    Mol Cancer Ther; 2017 Mar 06; 16(3):506-515. PubMed ID: 28138027
    [Abstract] [Full Text] [Related]

  • 23. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY.
    Anticancer Drugs; 2013 Nov 06; 24(10):1039-46. PubMed ID: 23962905
    [Abstract] [Full Text] [Related]

  • 24. Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer.
    Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, Raddrizzani L, Palmeri L, Banfi P, Bonazzina E, Misale S, Marrapese G, Leone A, Alzani R, Luo D, Hornby Z, Lim J, Veronese S, Vanzulli A, Bardelli A, Martignoni M, Davite C, Galvani A, Isacchi A, Siena S.
    J Natl Cancer Inst; 2016 Jan 06; 108(1):. PubMed ID: 26563355
    [Abstract] [Full Text] [Related]

  • 25. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, Zhu CQ, Li M, Ng C, Liu N, Pintilie M, Martin P, John T, Jurisica I, Leighl NB, Neel BG, Waddell TK, Shepherd FA, Liu G, Tsao MS.
    J Clin Oncol; 2015 Aug 01; 33(22):2472-80. PubMed ID: 26124487
    [Abstract] [Full Text] [Related]

  • 26. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E, Shien K, Torigoe H, Takeda T, Takahashi Y, Ogoshi Y, Yoshioka T, Namba K, Sato H, Suzawa K, Yamamoto H, Soh J, Okazaki M, Shien T, Tomida S, Toyooka S.
    Anticancer Res; 2019 Apr 01; 39(4):1767-1775. PubMed ID: 30952716
    [Abstract] [Full Text] [Related]

  • 27. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
    Longo SL, Padalino DJ, McGillis S, Petersen K, Schirok H, Politz O, Canute GW, Post DE.
    Invest New Drugs; 2012 Dec 01; 30(6):2161-72. PubMed ID: 22203214
    [Abstract] [Full Text] [Related]

  • 28. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M, Costa DB, Rangachari D.
    Ther Adv Respir Dis; 2016 Apr 01; 10(2):113-29. PubMed ID: 26620497
    [Abstract] [Full Text] [Related]

  • 29. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
    Oh DY, Jung K, Song JY, Kim S, Shin S, Kwon YJ, Oh E, Park WY, Song SY, Choi YL.
    BMC Cancer; 2017 Aug 10; 17(1):535. PubMed ID: 28806950
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, Xie Q.
    J Transl Med; 2015 Sep 17; 13():306. PubMed ID: 26381735
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations.
    Oguchi K, Araki H, Tsuji S, Nakamura M, Miura A, Funabashi K, Osada A, Tanaka S, Suzuki T, Kobayashi SS, Mizuarai S.
    Cancer Sci; 2023 Feb 17; 114(2):654-664. PubMed ID: 36282234
    [Abstract] [Full Text] [Related]

  • 38. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Zhang YW, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF.
    Mol Cancer Ther; 2013 Aug 17; 12(8):1429-41. PubMed ID: 23720767
    [Abstract] [Full Text] [Related]

  • 39. Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway.
    Taniguchi H, Yamada T, Takeuchi S, Arai S, Fukuda K, Sakamoto S, Kawada M, Yamaguchi H, Mukae H, Yano S.
    Cancer Sci; 2017 Jul 17; 108(7):1378-1385. PubMed ID: 28474864
    [Abstract] [Full Text] [Related]

  • 40. Pharmacokinetic-Pharmacodynamic-Efficacy Modeling of ONO-7579, a Novel Pan-Tropomyosin Receptor Kinase Inhibitor, in a Murine Xenograft Tumor Model.
    Iida H, Fujikawa R, Kozaki R, Harada R, Hosokawa Y, Ogawara KI, Ohno T.
    J Pharmacol Exp Ther; 2020 Jun 17; 373(3):361-369. PubMed ID: 32217770
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.